Charles River Laboratories International, Inc. (CRL) — Fair Value Analysis

Base-case fair value (P50): $186.92 · Current price: $150.85 · Verdict: Undervalued

Charles River Laboratories (CRL) is currently assessed as Fairly Valued based on our proprietary Monte Carlo simulations, despite trading below its median fair value. The stock's current price of $177.62 sits significantly below its calculated median fair value (P50) of $207.31, representing a potential upside of +16.7%. This implies that while the shares offer a discount, the market's current valuation falls within the expected range of outcomes for the Healthcare sector.

The Verdict on CRL

Our Monte Carlo simulations indicate a Fairly Valued assessment for Charles River Laboratories. The current $177.62 price offers a notable discount to its median fair value (P50) of $207.31, implying +16.7% upside. This suggests that while there is room for appreciation, the market's current pricing aligns within the broader distribution of fair value outcomes for CRL, and is not signaling an overvalued position.

How CRL stacks up against Healthcare

Within the Healthcare sector, Charles River Laboratories holds an average quality tier rating, reflecting its operational and financial health relative to peers. This average positioning suggests CRL is a steady performer. Combined with its current price of $177.62 and a median fair value (P50) of $207.31, the +16.7% gap to its P50 implies that CRL generally performs in line with sector expectations while still presenting an attractive discount.

What this means for investors

For investors, the Fairly Valued assessment of Charles River Laboratories at its $177.62 current price, compared to a median fair value (P50) of $207.31, suggests the market appropriately prices its fundamentals within the Healthcare sector. The observed +16.7% difference indicates potential for upside, but also reinforces the broader distribution of simulated outcomes. Given its average quality tier, CRL presents a balanced risk-reward profile, not signaling an overvalued position. For a complete understanding of CRL's fair value range, including bear-case and bull-case targets, sign up for FairCurve to see the full distribution and track CRL's fair value as new fundamentals are released.